Entrada Therapeutics, Inc.
http://www.entradatx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Entrada Therapeutics, Inc.
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Gene And Cell Therapy Clinical Holds Decline While Those For Drugs Hit 12-Year High
FDA’s Center for Biologics Evaluation and Research saw IND clinical holds for gene and cell therapies dropped to 70 in calendar year 2022, a 52% decline from 2018. Center for Drug Evaluation and Research’s total clinical holds in fiscal year 2022 were 380, the highest number in the past 12 years.
Duchenne Doldrums Continue As Entrada Hit With IND Clinical Hold
The US firm’s lead oligonucleotide asset, ENTR-601-44, has received a clinical hold notice after IND submission, adding to a growing list of companies in the Duchenne space facing setbacks.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice